The Broadening Utility of CAR T-Cell Therapy: Challenges and Opportunities to Expand Access

Program Description
The use of chimeric antigen receptor-modified (CAR) T-cell therapies is becoming widespread in the treatment of hematologic malignancies. CAR T-cell therapies are associated with unique care considerations including management of adverse effects and coordination of treatment plans with the multidisciplinary team. This activity will focus on approved CAR T-cell therapies as well as guideline recommendations for place in the treatment paradigm. Additionally, expert panelists will discuss factors impacting access to care, with an emphasis on how to integrate CAR T-cell therapies into clinical practice.

Target Audience: Managed care pharmacists

Type of Activity: Application

Release date: November 4, 2021

Expiration date: November 4, 2022

Time to complete activity: 1.5 hours

Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Explore clinical trial data for approved indications for chimeric antigen receptor-modified (CAR) T-cell therapies and their impact in cancer care
• Interpret guideline recommendations for implementation of CAR T-cell therapy in treatment pathways and management of associated adverse effects
• Examine payment mechanisms and associated therapy-specific factors to optimize the use of CAR T-cell therapy and improve access for patients

Pharmacy Times Continuing Education^™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-21-382-H01-P. The activity is available for CE credit through November 4, 2022.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Faculty

Rebecca Borgert, PharmD, BCOP, has the following relevant financial relationships with commercial interests to disclose:
Consultant: Seagen, Pfizer, Sanofi Genzyme

Mary Nauffal, PharmD, MS, BCOP, has no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Meg Taylor, PharmD, CPP; Liz Rauh; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with commercial interests to disclose.

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms